NIGHTINGALE HEALTH OYJ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.64 EUR | +3.14% |
|
+0.61% | +46.95% |
| Apr. 16 | Finland’s Nightingale Health Plots US Expansion | MT |
| Apr. 16 | Nightingale Health to Establish A Laboratory in the United States | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Based on current prices, the company has particularly high valuation levels.
- Revenue estimates are regularly revised downwards for the current and coming years.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +46.95% | 104M | - | ||
| +19.58% | 8.09B | C- | ||
| +32.03% | 4.3B | B- | ||
| -30.43% | 2.63B | C- | ||
| -15.20% | 1.41B | B | ||
| -26.60% | 1.31B | - | C+ | |
| -34.43% | 1.15B | - | ||
| +10.41% | 1B | C | ||
| -35.57% | 924M | - | ||
| -20.00% | 676M | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- HEALTH Stock
- Ratings Nightingale Health Oyj
